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Background: In inflammatory joint disease, such as osteoarthritis or arthritis, there is an increased level of
pro-inflammatory cytokines, such as interleukin-1β. These cytokines stimulate the expression and release of
matrix metalloproteases (MMP), leading to the degradation of cartilage extracellular matrix and subsequently mobility
difficulty and suffering for patients. The aim of this study was to examine the therapeutic potential of a fatty acid
copolymer in in vitro and in vivo models of cartilage inflammation.
Methods: Inflammation was mimicked in vitro by treatment of human articular chondrocytes with interleukin-1β.
Effects of a co-treatment with a copolymer of fatty acids (Ara 3000 beta®) were determined by evaluating MMP
production by RT-PCR and ELISA, NO release by Griess assay, and PGE2 expression by ELISA. In addition, in vivo analysis
(evolution of weight and edema) were also performed after injection of Freund adjuvant in rats treated or not with the
copolymer of fatty acids.
Results: The copolymer of fatty acids clearly reduces inflammation in joint. In vitro, it impairs IL1 stimulated-MMP
production and release, as well as the release of NO and PGE2 and the activation of NFκB. Furthermore, in vivo
experiments using adjuvant induced-arthritis corroborates the anti-inflammatory effects of the copolymer of fatty
acids, with a reduction of edemas, erythemas and ankylosis in arthritic rats.
Conclusions: The results support the hypothesis that a copolymer of fatty acids, such as Ara 3000 beta®, is a powerful
anti-inflammatory compounds, suggesting that it has a potential for preventing cartilage degradation associated with
chronic inflammatory joint disease.
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Joint diseases such as the degenerative joint disease
osteoarthritis (OA) and the inflammatory disease
rheumatoid arthritis (RA) are characterized by dramatic
degradation of articular cartilage, caused by overexpres-
sion of matrix metalloproteinases (MMPs), and reduced
anabolic activity of chondrocytes. The MMPs, produced
by chondrocytes, are zinc-containing proteinases that
degrade cartilage and cause severe joint damage. MMP-1
and MMP-13, particularly cause the digestion of type II* Correspondence: catherine.bauge@unicaen.fr
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unless otherwise stated.collagen, the principal collagenous material in hyaline
cartilage. MMP-3 is also involved in the breakdown of
extracellular matrix by degrading proteoglycans.
IL-1β has been detected in the synovial fluid of OA
patients [1] and plays a major role in joint diseases,
causing overproduction of prostaglandin E2 (PGE2), re-
active oxygen species (ROS), nitric oxide (NO), and
MMPs, which all contribute to the degradative process
of cartilage. IL-1β also reduces levels of inhibitors of
MMPs (tissue inhibitors of MMPs, TIMP) in arthritic
joints and decreases biosynthesis of type II collagen and
aggrecan, limiting the repair potential of cartilage. These
effects have been confirmed by in vivo studies showing
that intraarticular administration of IL-1β into animalThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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whereas injection of IL-1 receptor antagonist (IL-1ra)
protects cartilage in arthritic joints. Regarding these
data, numerous in vitro studies have evaluated the inter-
est of anti-arthritic molecules using their ability to coun-
teract IL-1 effects in models of inflammatory joint
diseases. Such studies have highlighted the anti-
inflammatory effects of tested drugs by measuring the
repression of expression of inflammatory markers such
as MMP levels, PGE2 or NO induced by IL-1 [2]. However,
even if IL-1β is a crucial factor in cartilage degradation
mechanisms, other proinflammatory cytokines, especially
TNF-α and IL6, play also major roles and can strongly
stimulate inflammation in arthritis.
The main objective of drugs used in joint diseases,
such as non steroidal anti-inflammatory drugs (NSAIDs),
TNF-α inhibitors, or IL-1 receptor antagonists, is symp-
tomatic management, reducing both pain and underlying
inflammation [3]. However, given the cost of such biologic
agents and their limited efficacy in some patients [4,5],
there has been a great demand for the development of
novel therapeutic agents.
Certain polyunsaturated fatty acids are beneficial to
the health of mammals. For instance, long chain n-3
fatty acids are present in fish and marine mammals, and
epidemiological data indicate a correlation between fish-
wealthy diets and reduced incidence of inflammatory
diseases [6]. In addition, in a variety of conditions, in-
cluding rheumatoid arthritis or osteoarthritis, these fatty
acids have been shown to offer therapeutic activity [7-9].
This may be associated with increased collagen synthesis
and decreased amounts of the inflammatory mediator
prostaglandin E2 as reported in fibroblasts in vitro [10].
At contrary, n-6 fatty acids have been reported to induce
IL-1, IL-6, TNF-α and PGE2. However, n-3 fatty acids
inhibit n-6 fatty acid induced-cytokine expression [11].
More recently, it has been shown that veterinary thera-
peutic diet rich in omega-3 fatty acids improved the
locomotor disability and the performance in activities of
daily living of OA dogs [12]. A beneficial effect was also
shown in OA-prone Dunkin Hartley strain guinea pigs
on a diet rich in long chain omega 3 fats with an im-
provement of OA degree and severity [13].
Besides, a copolymer of fatty acids, composed of oleic
acid, palmitic acid and stearic acid, called Ara 3000 beta®
has also been shown to reduce osteoarthritis symptoms
in dogs, with a reduction of lameness and pain [14]. This
injectable gel also inhibits the synthesis of leukotriene
and the degranulation of mast cells.
Here, we wanted to evaluate the anti-inflammatory
functions of this fatty acid copolymer in joint. So, we
evaluated its effects on IL-1-induced MMP production
and other markers of inflammation in articular chondro-
cyte culture. Then, we used an in vivo model of arthritisto evaluate the therapeutic interest of this fatty acid co-
polymer against inflammatory joint diseases.
Methods
Reagents
Reagents were supplied by Invitrogen (Fisher Bioblock
Scientific, Illkirch, France) unless otherwise noted. IL-1β
(Sigma-Aldrich, St. Quentin Fallavier, France) was resus-
pended in phosphate buffered saline (PBS) with BSA. Ol-
igonucleotides were supplied by Eurogentec (Angers,
France). The copolymer of fatty acids Ara 3000 beta®
(oleic acid: 8.75 mg/ml, palmitic acid: 5.4 mg/ml and ste-
aric acid: 4 mg/ml) was supplied by Sexmoor Laboratory
and diluted at 1:10 in Phosphate Buffer Saline (PBS) sup-
plemented with 0.25% Bovine Serum Albumin (BSA).
This solution was used at two dilutions (1:250 and
1:1000) in 10% FCS and 0.25% BSA-containing RPMI
medium to reach the final concentrations (1:250 dilution
corresponding to 1.28 10−4 M oleic acid, 1.88 10−4 M
palmitic acid, and 2.84 10−4 M stearic acid; or 1:1000
dilution corresponding to 3.2 10−5 M oleic acid, 4.7 10−5 M
palmitic acid, and 7,11 10−5 M stearic acid).
Cell culture and treatments
Human articular chondrocytes (HAC) were prepared
from femoral heads of patients with hip fractures All do-
nors signed agreement forms before the surgery, accord-
ing to local legislation (agreement obtained from local
ethical committee, “Comité de Protection des Personnes
Nord Ouest III”). Cells were isolated and cultured as
previously described [15]. Cartilage samples were cut
into small slices, and chondrocytes were isolated by se-
quential digestion by type XIV protease (Sigma-Aldrich,
St. Quentin Fallavier, France) and then type I collagenase
(from Clostridium histolyticum; Invitrogen, Fisher Bio-
block Scientific, Illkirch, France). The cell suspension
was filtered, seeded in plastic vessels at a density of 4 ×
104 cells/cm2 and cultured in Dulbecco’s modified Ea-
gle’s medium (DMEM) supplemented with 10% fetal calf
serum (FCS; Invitrogen) and antibiotics, in an atmos-
phere of 5% CO2. The medium was changed twice a
week.
On day 8, the cells were incubated with 10% FCS and
0.25% BSA-containing RPMI medium with Ara 3000
beta® (dilution 1:1000 or 1:250). The next day, medium
were changed and cells were incubated with fresh Ara
3000 beta® according the same protocol, and supple-
mented or not with interleukin-1β (IL-1β) (1 ng/ml;
Sigma-Aldrich, St. Quentin Fallavier, France).
Viability assay
Viability was evaluated by tetrazolium colorimetric
WST1 assay (Roche Diagnostics, Meylan, France). HAC
were plated into 96-well microtiter plates. At 70%
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added in all wells, except control. Then, microplates
were incubated for 48 h. One hour before the end of in-
cubation, 10 μl of WST1 solution was added to all wells.
Optical density was measured on a spectrophotometer
plate reader (1420 Multilabel Counter, Perkin Elmer) at
450 nm. A well without cells containing complete
medium and WST1 only acted as blanks. Survival was
calculated according to the formula: ODtest/ODcontrol.
RNA extraction and real-time reverse
transcription–polymerase chain reaction
Total RNA from primary HAC cultures were extracted
using Trizol. After extraction, 1 μg of DNase-I–treated
RNA was reverse transcribed into cDNA in the presence
of oligodT and Moloney murine leukemia virus reverse
transcriptase. The reaction was carried out at 37°C for
1 h followed by a further 10-min step at 95°C. Amplifi-
cation of the generated cDNA was performed by real-
time PCR in an Applied Biosystems SDS7000 apparatus
with appropriate primers designed with Primer Express
software. The relative mRNA level was calculated with
the 2–ΔΔCT method.
Elisa
PGE2 and MMPs released into conditioned media was
quantified using commercially available enzyme im-
munoassay kit (R&D Systems, Lille, France). Absorbance
was determined at 450 nm with a wavelength correction
set at 540 nm.
NO assay
Generation of nitric oxide was determined by measuring
nitrite accumulation in culture supernatants using Griess
reagent (1% sulphanilamide and 0.1% N-(1-naphthyl)-
ethylenediamine dihydrochloride in 5% H3PO4; Sigma-
Aldrich, St. Quentin Fallavier, France). Sample and
Griess reagent (150 μl of each) were mixed and incu-
bated for five minutes; the absorption was estimated by
a plate reader (1420 Multilabel Counter, Perkin Elmer)
at 540 nm. Sodium nitrite (NaNO2, Sigma-Aldrich, St.
Quentin Fallavier, France) was used as positive control.
Nuclear extracts and EMSA
Extracts were prepared as previously described [16]. The
protein amount was determined by the Bradford colori-
metric procedure (Bio-Rad, Marnes-la-Coquette, France).
For electrophoretic mobility shift assay (EMSA), 5 fento-
moles of biotinylated probe (corresponding to consensus
NFkB binding site) and 5 μg of nuclear proteins from
chondrocytes were incubated at room temperature for
30 min in binding buffer (50 mM Tris–HCl pH 8, 1 mM
dithiothreitol, 750 mM KCl, 2.5 mM EDTA, 0.5% Triton-
X100; 65.5% glycerol (v/v)) with poly-dIdC (1 μg). Thenall samples were loaded on a nondenaturating acrylamide
gel (7%). After separation, probes and proteins were elec-
trotransferred on PVDF membrane, which was incubated
with streptavidin-conjugated peroxydase (Sigma). The sig-
nals were revealed with SuperSignal West Pico Chemilu-
minescent Substrate (Pierce Perbio Science, Brébières,
France) and exposed to X-ray film.
In vivo experiments
Animal experimental procedures were performed in the
animal facility of Valbex Center Lyon1 (Villeurbanne,
France) according to local legislation. The procedure
was approved by internal ethics committee of Valbex fa-
cility. The discussions addressed the ethics aspect of
study and the respect of 3Rs. Researchers held a nom-
inative authorization to animal experiment provided by
the French Ministry of Agriculture. This authorization
also supported the ethics of studies with animal
appearance.
The animals were kept in the animal facility (Valbex
Center Lyon1,Villeurbanne, France) and allowed to
acclimatize to the laboratory conditions (temperature
23 ± 2°C with a 12 h light–dark cycle). Animals had free
access to standard rat chow and water. Each animal was
used only once as all animals were euthanized at the end
of each experiment. The animals were humanely han-
dled throughout the experiment in accordance with
internationally accepted ethical principles for laboratory
animal use and care, and all efforts were made to
minimize animal suffering. Euthanasia was performed
using carbodioxyde inhalation or barbiturate overdosis.
Adjuvant-induced arthritis (AIA) was produced on day
0 by an intradermal injection of 500 μl of a complete
Freund adjuvant suspension (DIFCO, ref 0638–607) into
the right hind paw of male Wistar EOPS rats under brief
anesthesia with isoflurane (<3 minutes, 4% isoflurane).
The development of AIA was assessed by paw volume
changes and appearance of secondary lesions. The volume
of the injected and noninjected hind paw was determined
by plethysmography. Measurements were performed over
a 30-day period. Body weight was assessed daily. Arthritis
severity score was evaluated in a scale going from 0 to 4
with 0 corresponding to no erythema and no inflamma-
tion; 1: cutaneous erythema, 2: moderate inflammation
(edema) and erythema; 3: severe inflammation; and 4: very
severe inflammation with ankylosis. Scoring was always
done by the same person in a blind way.
For experiments, the animals (n = 10 per group) were
divided into 3 treatment groups: (1) animals with arth-
ritis which received intramuscular injections of 600 μl of
physiological serum one day before Freund adjuvant in-
jection, and 300 μl of physiological serum at day 6, 9
and 12 (group control); (2) animals with arthritis which
received intramuscular injection of 600 μl of Ara 3000
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300 μl of the copolymer of fatty acids at day 6, 9 and 12
(group Ara 3000 beta®), and (3) animals with arthritis
which daily received aqueous solution of acetylsalicylic
acid (200 μg/g) per os, from day −1 to day 12.
Statistical analysis
For in vitro experiments, three different experiments
were performed. The values are means ± SEM and the
significance of differences was calculated with Student’s t
test. For in vivo experiments, 10 animals were used for
each group, and ANOVA tests (repeated measures)
followed by Fisher PLSD test, and Student’s test were
done.
Results
Toxicity of the fatty acid copolymer
In order to evaluate the putative effect of the fatty acid
copolymer Ara 3000® on chondrocyte proliferation or
toxicity, we evaluated the number of viable chondrocytes
using WST-1 assay. Our analyses (Figure 1) showed that
this copolymer of fatty acids (at dilution ≥ 1:250) had no
effect on survival or proliferation of chondrocytes. How-
ever, we observed a strong toxicity at higher concentration.
Effect of the copolymer of fatty acids on MMPs
We pursued this study by analyzing IL-1 induced-
expression of MMP1, MMP3 and MMP13 (Figure 2). A
48 h-treatment with the copolymer of fatty acids clearly
prevented IL-1ß-stimulation of MMP mRNA levels, par-
ticularly at 1:250. This effect was more significant when
cells were pre-incubated with the copolymer of fattyFigure 1 Effect of Ara 3000 beta® on chondrocyte growth. Human arti
with increasing concentration of Ara 3000 beta® (1:1000 to 1: 100) for 48 h.
Values were normalized to OD from untreated cells.acids for 24 h before stimulation by IL-1. That’s why we
use this experimental condition for further study.
We investigated the release of MMPs in medium by
ELISA (Figure 3). Our experiments show that Ara 3000
beta® treatment reduces IL-1 induced-release of MMPs.
However, this effect was statistically significant only for
MMP1 at dilution 1:1000 and MMP3 at dilution 1:250.
Effects of the copolymer of fatty acids on IL-1
induced-release of NO and PGE2
We examined whether Ara 3000 beta® influenced the re-
lease of inflammatory molecules implicated in joint dis-
eases, including NO and PGE2 (Figure 4A and B). By
Griess assay or ELISA, we showed that this copolymer
of fatty acids at dilution 1:1000 and 1:250 significantly
reduced IL-1 induced-release of NO and PGE2.
Effects of the copolymer of fatty acids on IL-1 induced-
activation of NFkB
To determine whether these anti-inflammatory effects of
Ara 3000 beta® could be associated with modulation of
NF-kB activation, we evaluated DNA binding activity of
NFκB by EMSA (Figure 4C). While IL-1β induced NFkB
binding to DNA, this binding was impaired by Ara 3000
beta® co-treatment, confirming the anti-inflammatory ef-
fect of this fatty acid copolymer.
Effects of a fatty acid copolymer in vivo arthritis model
Finally, we studied anti-inflammatory effect of the co-
polymer using adjuvant-induced arthritis (AIA) model in
rats. Following injection of complete Freund’s adjuvant
(CFA), we observed a significant inflammatory reaction
in the right hind paw as soon as the first day, and thecular chondrocytes were cultured for 6–7 days. Then, cells were treated
At the end of incubation, cell growth was evaluated using Wst-1 assay.
Figure 2 Effect of Ara 3000 beta® on IL-1 induced MMP mRNA expression. Human articular chondrocytes were cultured for 6–7 days. Then,
they were incubated with IL-1β (1 ng/ml) (IL1) or vehicle (C) in the presence or not of Ara 3000 beta® (dilution 1:250 or 1:1000). At the end of the
incubation, MMP mRNA level was evaluated by RT-PCR. A- Cells were co-treated with IL-1 and Ara 3000 beta® for 48 h. B - Cells were incubated
with Ara 3000 beta® for 24 h. Then medium was changed and cells were cotreated with IL-1 and Ara 3000 beta® for 24 h.
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20 days. An inflammatory response in the non-injected
paw (left hind paw) was observed from the tenth day
after the induction of AIA and increased gradually until
day 21. Treatment of rats with acetylsalicylic acid did
not significantly reduce inflammation. However, treat-
ment of rats with Ara 3000 beta® reduced the development
of edema in the right paw (injected with CFA) (p < 0.01
from day 12) and also in the left paw, which was not
injected with CFA (p < 0.02 from day 16) (Figure 5). In
addition, arthritis severity score from hind paws and tails
shows a benefit of the copolymer of fatty acids (p < 0.05
from day 12). From day 14, animals without treatment
develop a moderate and then severe inflammation(score > 2), whereas animals treated with the copolymer of
fatty acids show only a weak inflammation (score < 1.5).
Concerning the weight of the animals, we observed an
increased progressively until the 12th day, when the sys-
temic manifestations of the disease began, at which time
a slight weight loss occurred. Interestingly, Ara 3000
beta®-treated rats continued to grow until the end of
experiments (day 30) (p < 0.03 from day 18).
Discussion
This work investigated the therapeutic potential and
anti-inflammatory effects of a copolymer of fatty acids
composed of oleic acid, palmitic acid and stearic acid
(Ara 3000 beta®) in vitro and in vivo in joint.
Figure 3 Effect of Ara 3000 beta® on IL-1 induced MMP release. Human articular chondrocytes were cultured for 6–7 days. At 80% confluency,
cells were preincubated with Ara 3000 beta® (dilution 1:250 or 1:1000). The day after, medium was changed and cells were cotreated with IL-1 (IL1) or
vehicle (C), and Ara 3000 beta® for 24 h. At the end of the incubation, release of MMPs was evaluated by ELISA. (Mean quantities of MMP released in
untreated wells: MMP1:22 μg; MMP3:18 μg; MMP13:188 ng.)
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release, in a physiologically relevant in vitro model of
inflammatory joint disease. IL-1β treatment was used at1 ng/ml as in previous studies [16,17], concentration
which powerfully stimulated inflammation and MMP
production.
Figure 4 Effect of Ara 3000 beta® on NO and PGE2 release, and NFκB DNA binding. Chondrocytes were pre-incubated 24 hours with Ara
3000 beta® or vehicle, and then they were treated with IL-1β (IL1) or vehicle (C), in the presence or not of Ara 3000 beta® for 24 h. A, B- At the
end of treatment, mediums were collected, and NO and PGE2 levels were determined in medium by Griess assay (A) and ELISA (B), respectively.
Histograms represent the percentage of induction of NO or PGE2 in Ara 3000 beta® treated-cells normalized to cells treated with IL-1 without Ara
3000 beta®. C- Electrophoretic mobility shift assay (EMSA) were performed using NFkB consensus binding probe, incubated with nuclear extracts
from chondrocytes treated as previously. Arrow indicates the band corresponding to NFkB binding.
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the expression of several genes implicated in the catabol-
ism of extracellular matrix and its pathological dysfunc-
tion. We found that Ara 3000 beta® was capable of
preventing IL-1-stimulated MMP-1, MMP3 and MMP13
expression and release. These data suggest a protective
effect of fatty acid copolymer on cartilage degradation
induced by interleukin-1β.
In vitro, reduction of MMP expression was more im-
portant when Ara 3000 beta® was used in pre-treatment,
suggesting that this copolymer of fatty acids should be
also use as preventive treatment. In this condition
(24 h-pretreatment with Ara 3000 beta® followed of
24 h-treatment with Ara 3000 beta® in the presence of
IL-1β), we show that this fatty acid strongly decreases
the IL-1 induced-expression of MMPs at mRNA level
(>40%). This effect was weaker when we evaluate MMP
release in medium. However, it is noteworthy that 24 h-
incubation with IL-1 induces a weak release of MMPs in
medium, whereas it is sufficient to induce NFκB activation
and a strong increase of MMP expression at mRNA level.Interestingly, this reduction of MMP production by
Ara 3000 beta® can be correlated with Bernadat’s obser-
vations which had showed, by proline release assay, that
Ara 3000 beta® decreases protein degradation in articular
chondrocytes [18].
In addition, we showed a clear anti-inflammatory effect
of the copolymer of fatty acids, since it decreases both
NFκB pathway activation and the release of inflammatory
molecules such as NO and PGE2. This anti-inflammatory
effect may prevent proinflammatory leukocyte adhesion
receptor expression, and subsequent leukocyte-endothelial
interaction. Therefore, the beneficial effect of the copoly-
mer of fatty acids may be even more profound and longer
lasting in vivo, where broader anti-inflammatory circuits
can be engaged. This is in agreement with our in vivo ob-
servations which have showed using adjuvant-induced
arthritis model, that Ara 3000 beta® has an anti-
inflammatory effect on vascular and cellular phase of in-
flammation, characterized by the maintenance of rat
growth and a reduction of edema and inflammation. This
suggests that Ara 3000 beta® counteracts inflammation
Figure 5 Effect of Ara 3000 beta® in arthritis rat. Arthritis was induced by injection of Freund Adjuvant. Then, rats were treated or not with
Ara 3000 beta® or acetylsalicylic acid (aspirin), and edema (A and B), arthritis severity score (C) and body weight (D) were determined each days
during one month. Graphs represent mean values from 10 animals ± SEM.
Baugé et al. Journal of Inflammation  (2015) 12:17 Page 8 of 9induced by IL-1 as shown by our in vitro data, but also
that this copolymer of fatty acid may also reduce TNF-a
and IL-6 effects, since these cytokines are strongly induce
during adjuvant induced arthritis rat model [19]. However,
other analysis would be required to confirm this hypoth-
esis. Interestingly, we found a better effect of fatty acid
polymer compared to acetylsalicylic acid. These data sup-
port the validity of clinical cases showing a benefit of Ara
3000 beta® against joint disease in dogs [14,20], and bringthe proof of the anti-inflammatory effects of this fatty acid
in articular chondrocytes.
The molecular mechanism by which Ara 3000 beta®
exerts its anti-inflammatory effects is still unknown.
However, several hypotheses may be proposed. This co-
polymer of non-esterified fatty acids (palmitic, oleic and
stearic acids) might be incorporated into the phospho-
lipids of cell membranes, or act via surface or intracellu-
lar “fatty acid receptors”, such as peroxisome proliferator
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membrane phospholipid fatty acid composition may in-
fluence the function of cells. It may alter physical prop-
erties of the membrane by maintaining membrane order
(“fluidity”) and modifying lipid raft formation. This could
affect NFkB signaling pathway [21], leading reduction of
MMP gene expression.
Conclusions
In conclusion, this report shows that a copolymer of fatty
acids such as Ara 3000 beta® reduces inflammation in
joint. In vitro, it impairs IL-1 stimulated-MMP production
and release, as well as the release of NO and PGE2 and
the activation of NFκB. Furthermore, in vivo, it reduces
edemas, erythemas and ankylosis in arthritic rats. Conse-
quently, fatty acids are powerful anti-inflammatory mole-
cules, and may be used to treat joint disease such as
arthritis or osteoarthritis.
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